NASDAQ: ARVN | Healthcare / Biotechnology / USA |
52.48 | -1.64 | -3.03% | Vol 229.53K | 1Y Perf -37.72% |
Aug 16th, 2022 16:00 DELAYED |
BID | 45.00 | ASK | 84.27 | ||
Open | 53.92 | Previous Close | 54.12 | ||
Pre-Market | - | After-Market | 52.48 | ||
- - | - -% |
Target Price | 102.81 | Analyst Rating | Strong Buy 1.40 | |
Potential % | 95.90 | Finscreener Ranking | ★★★ 49.54 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★★+ 49.70 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★★★+ 62.68 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 27.57 | Earnings Rating | Strong Sell | |
Market Cap | 2.79B | Earnings Date | 4th Aug 2022 | |
Alpha | 0.05 | Standard Deviation | 0.43 | |
Beta | 1.98 |
Today's Price Range 52.420.00 | 52W Range 34.9098.67 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | -9.50% | ||
1 Month | 5.28% | ||
3 Months | 15.77% | ||
6 Months | -24.36% | ||
1 Year | -37.72% | ||
3 Years | 119.67% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -28.86 | |||
ROE last 12 Months | -37.19 | |||
ROA (5Y Avg) | -7.02 | |||
ROA last 12 Months | -22.73 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -37.47 | |||
Return on invested Capital Q | -10.10 | |||
Return on invested Capital Y | -6.67 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 5.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-12.20 | ||||
4.32 | ||||
31.60 | ||||
5.60 | ||||
5.80 | ||||
9.77 | ||||
4.32 | ||||
12.60 | ||||
1.56B | ||||
Forward PE | -10.93 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.70 | ||||
5.80 | ||||
0.01 | ||||
0.01 | ||||
-2 976.90 | ||||
Leverage Ratio | 2.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-247.60 | ||||
-239.80 | ||||
-303.80 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
91.12M | ||||
1.71 | ||||
32.56 | ||||
44.90 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -1.02 | -1.32 | -29.41 |
Q01 2022 | -0.85 | -1.20 | -41.18 |
Q04 2021 | -0.78 | -1.00 | -28.21 |
Q03 2021 | 2.85 | -0.94 | -132.98 |
Q02 2021 | -0.84 | -1.03 | -22.62 |
Q01 2021 | -0.78 | -0.84 | -7.69 |
Q04 2020 | -0.78 | -0.99 | -26.92 |
Q03 2020 | -0.67 | -0.79 | -17.91 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -1.02 | -13.33 | Negative |
9/2022 QR | -0.78 | 4.88 | Positive |
12/2022 FY | -4.36 | -18.48 | Negative |
12/2023 FY | -4.98 | 0.99 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -1.02 |
Estimates Count | 12 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 229.53K |
Shares Outstanding | 53.21K |
Shares Float | 44.74M |
Trades Count | 6.51K |
Dollar Volume | 12.19M |
Avg. Volume | 402.06K |
Avg. Weekly Volume | 425.22K |
Avg. Monthly Volume | 384.14K |
Avg. Quarterly Volume | 396.81K |
Arvinas Inc. (NASDAQ: ARVN) stock closed at 52.48 per share at the end of the most recent trading day (a -3.03% change compared to the prior day closing price) with a volume of 229.53K shares and market capitalization of 2.79B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 133 people. Arvinas Inc. CEO is John Houston.
The one-year performance of Arvinas Inc. stock is -37.72%, while year-to-date (YTD) performance is -36.11%. ARVN stock has a five-year performance of %. Its 52-week range is between 34.9 and 98.67, which gives ARVN stock a 52-week price range ratio of 27.57%
Arvinas Inc. currently has a PE ratio of -12.20, a price-to-book (PB) ratio of 4.32, a price-to-sale (PS) ratio of 31.60, a price to cashflow ratio of 5.60, a PEG ratio of 2.32, a ROA of -22.73%, a ROC of -37.47% and a ROE of -37.19%. The company’s profit margin is -%, its EBITDA margin is -239.80%, and its revenue ttm is $91.12 Million , which makes it $1.71 revenue per share.
Of the last four earnings reports from Arvinas Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.02 for the next earnings report. Arvinas Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arvinas Inc. is Strong Buy (1.4), with a target price of $102.81, which is +95.90% compared to the current price. The earnings rating for Arvinas Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arvinas Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arvinas Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.11, ATR14 : 3.50, CCI20 : 22.06, Chaikin Money Flow : 0.08, MACD : 1.97, Money Flow Index : 52.77, ROC : 2.36, RSI : 38.94, STOCH (14,3) : 53.44, STOCH RSI : 0.00, UO : 56.31, Williams %R : -46.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arvinas Inc. in the last 12-months were: Bradley Margus (Sold 29 940 shares of value $2 545 168 ), Briggs Morrison (Option Excercise at a value of $259 008), Briggs Morrison (Sold 20 960 shares of value $1 374 021 ), Briggs W. Morrison (Option Excercise at a value of $518 016), Briggs W. Morrison (Sold 41 920 shares of value $2 766 636 ), Ian Taylor (Option Excercise at a value of $789 388), Ian Taylor (Sold 40 000 shares of value $3 141 062 ), John G. Houston (Option Excercise at a value of $715 040), John G. Houston (Sold 40 000 shares of value $3 525 723 ), Liam Ratcliffe (Option Excercise at a value of $544 531), Liam Ratcliffe (Sold 662 094 shares of value $51 367 310 ), Sean A. Cassidy (Option Excercise at a value of $240 000), Sean A. Cassidy (Sold 15 000 shares of value $1 050 000 ), Timothy M. Shannon (Sold 400 000 shares of value $34 512 491 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.
CEO: John Houston
Telephone: +1 203 535-1456
Address: 395 Winchester Avenue, New Haven 06511, CT, US
Number of employees: 133
Mon, 09 May 2022 12:42 GMT Analysts Conflicted on These Healthcare Names: Lantheus (LNTH), Arvinas Holding Company (ARVN) and Prestige Consumer Healthcare (PBH)
- TipRanks. All rights reserved.Wed, 23 Mar 2022 13:15 GMT Arvinas Holding Company (ARVN) Received its Third Buy in a Row
- TipRanks. All rights reserved.Thu, 03 Mar 2022 10:17 GMT Arvinas Holding Company (ARVN) Gets a Buy Rating from Leerink Partners
- TipRanks. All rights reserved.Tue, 15 Feb 2022 09:31 GMT Arvinas Holding Company (ARVN) Receives a Buy from Leerink Partners
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.